<?xml version="1.0" encoding="UTF-8"?>
<p>Withanoside IV, another chemical constituent of 
 <italic>Withania</italic>, when administered orally at the dose of 10 micromol/kg prevented cognitive impairment in the experimental model of AD [
 <xref rid="B44-brainsci-10-00964" ref-type="bibr">44</xref>]. Sominone (1 microM) a metabolite of Withanoside IV, induced axonal and dendritic regeneration and synaptic reconstruction in cultures of rat cortical neurons damaged by the amyloid peptide, Aβ(25–35) [
 <xref rid="B44-brainsci-10-00964" ref-type="bibr">44</xref>]. Therefore, withanoside IV may act as a prodrug, with sominone as the active component. The enhancement of spatial memory by sominone may be attributed to neuritic outgrowth, which is mediated by the neurotrophic factor receptor, RET [
 <xref rid="B159-brainsci-10-00964" ref-type="bibr">159</xref>]. Methanolic root extract dose dependently enhanced in-vitro dendrite formation in human neuroblastoma cells [
 <xref rid="B159-brainsci-10-00964" ref-type="bibr">159</xref>]. A study carried out by Jayaprakasam et al. [
 <xref rid="B160-brainsci-10-00964" ref-type="bibr">160</xref>] stated that withanamides (A/C) present in 
 <italic>W. somnifera</italic> fruits protect pheochromocytoma-(PC-12) from β-amyloid induced toxicity. In the same study, β-amyloid fibril formation was prevented, possibly due to the presence of a serotonin moiety in both withanamide compounds.
</p>
